ENVB — Enveric Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Enveric Biosciences Gets New US Patent For Tryptamine-Derived Prodrugs
Brief: Enveric Biosciences Inc Completes Manufacturing Of Eb-373 To Supply Drug Material For Completion Of Preclinical Program
Brief: Enveric Biosciences Q2 Net Income USD -6.4 Mln
Enveric Biosciences Inc expected to post a loss of 65 cents a share - Earnings Preview
Brief: Enveric Biosciences Reports Results From Preclinical Studies Of Lead Candidate Eb-373
Brief: Enveric Biosciences Reports Positive Results From Animal Studies For EB-373
Brief: Enveric Biosciences Announces Development Of Phase 1-Ready Formulation For EB-373 And Initiation Of Scaled Up Manufacturing
Brief: Enveric Biosciences Receives Notice Of Allowance From U.S. Patent & Trademark Office For Patent Application Of Evm301 Series Of Molecules
U.S. STOCKS ON THE MOVE-Nvidia, GeoVax Labs, Freshpet
Enveric Biosciences surges on second patent notice for anxiety disorder drug
Brief: Enveric Biosciences Inc- On May 18, Eliminated The Positions Of President And Chief Operating Officer
Brief: Enveric Biosciences Receives Notice Of Allowance From USPTO For C4-Carboxylic Acid-Substituted Tryptamine Derivatives For Next Generation Psilocin Prodrug
U.S. STOCKS ON THE MOVE-Brady, Madison Square Garden Entertainment, Bowlero
U.S. STOCKS ON THE MOVE-Hawkins, Netflix, Alibaba Group
Enveric Biosciences to receive anxiety disorder drug patent, shares jump
Enveric Biosciences to receive anxiety disorder drug patent, shares up
Brief: Enveric Biosciences Receives Notice Of Allowance From Uspto For Novel Prodrug Of Psilocin
Brief: Enveric Biosciences Reports First Quarter 2023 Financial Results And Operational Highlights
Brief: Enveric Biosciences Reports Fourth Quarter Results